Depomed (DEPO) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Leerink Keeps Depomed (DEPO) at 'Outperform'; Disappointing Q3 Steps-up Pressure to Sell
November 8, 2016 11:00 AM ESTLeerink affirms its Outperform rating and $22 price target on Depomed (Nasdaq: DEPO) following Q3 results and update on Monday night.
Analyst Jason M. Gerberry commented today, DEPO reported disappointing 3Q results, missing our/Streets revenue forecasts by 13% and reducing 2016 revenue guidance for the third consecutive qtr. The miss... More
Cantor Fitzgerald Downgrades DepoMed Inc (DEPO) to Hold
November 8, 2016 7:41 AM ESTCantor Fitzgerald downgraded DepoMed Inc (NASDAQ: DEPO) from Buy to Hold with a price target of $23.00 (from $25.00).
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $22.89 yesterday.
... More


